Read More Pharma Industry News Wockhardt delivers strong FY25 EBITDA, but net loss persists amid US restructuring drag Wockhardt posts a 67% EBITDA jump in FY25, but Q4 PAT remains negative. Find out how novel antibiotics like Zaynich and Miqnaf are shaping investor sentiment. byPallavi MadhirajuMay 29, 2025